Lise‐Lotte Olsson
AstraZeneca (Sweden)(SE)
Publications by Year
Research Areas
Computational Drug Discovery Methods, Alzheimer's disease research and treatments, Chemical Synthesis and Analysis, Cholinesterase and Neurodegenerative Diseases, Asymmetric Synthesis and Catalysis
Most-Cited Works
- → Application of Fragment-Based Lead Generation to the Discovery of Novel, Cyclic Amidine β-Secretase Inhibitors with Nanomolar Potency, Cellular Activity, and High Ligand Efficiency(2007)211 cited
- → Inhibition of Lipid Peroxidation by Spin Labels(1989)177 cited
- → Discovery of a Novel Warhead against β-Secretase through Fragment-Based Lead Generation(2007)148 cited
- → Discovery of AZD3839, a Potent and Selective BACE1 Inhibitor Clinical Candidate for the Treatment of Alzheimer Disease(2012)136 cited
- → An Integrated Approach to Fragment-Based Lead Generation:Philosophy, Strategy and Case Studies from AstraZenecas Drug Discovery Programmes(2007)127 cited
- → Engineering the surface properties of a human monoclonal antibody prevents self-association and rapid clearance in vivo(2016)121 cited
- → Design and Synthesis of β-Site Amyloid Precursor Protein Cleaving Enzyme (BACE1) Inhibitors with in Vivo Brain Reduction of β-Amyloid Peptides(2012)99 cited
- → Peroxidase-catalyzed Oxidation of Eugenol: Formation of a Cytotoxic Metabolite(s)(1989)97 cited
- → Engineering Neprilysin Activity and Specificity to Create a Novel Therapeutic for Alzheimer’s Disease(2014)72 cited
- → New Aminoimidazoles as β-Secretase (BACE-1) Inhibitors Showing Amyloid-β (Aβ) Lowering in Brain(2012)65 cited